HeartBeam Stock Surges 62% After FDA Breakthrough Device Designation

HeartBeam Inc. (BEAT) saw its stock price surge by 62% to 71 cents after receiving a Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its at-home heart attack assessment tool. The designation, granted in under 30 days, accelerates the review process compared to the standard 60-day window. This recognition could also expedite Medicare coverage for the device, as it serves as a prerequisite for certain expedited pathways.

The HeartBeam System leverages the company’s existing 3D ECG platform, which is already FDA-cleared for arrhythmia detection. The technology captures the heart’s electrical activity from three angles, enabling early detection of heart attacks at home. This contrasts with the current gold standard, the 12-lead ECG, which is primarily used in hospitals and clinics. HeartBeam estimates the heart attack detection market at $15 billion, part of a broader $40 billion-plus cardiac platform market.

Supporting data for the device came from proof-of-concept results presented at the 2025 American Heart Association Scientific Sessions and findings from the ALIGN-ACS pilot study, which enrolled 134 patients. The company plans to collaborate with the FDA on designing a larger, multicenter pivotal study, with patient enrollment expected to begin shortly after finalizing the study design. Additionally, HeartBeam will share more data from the ALIGN-ACS study at the upcoming TCT conference and provide updates on its HEADSTART-ACS study.

The Breakthrough Device Designation is not an approval but a fast-track label that grants HeartBeam priority access to FDA reviewers. This includes closer collaboration on study design and a quicker path toward eventual clearance. The designation also supports reimbursement efforts, potentially allowing qualifying devices to receive national coverage determinations the same day they clear regulatory review.